Contrasting Synaptogenix (TAOX) and Its Rivals

Synaptogenix (NASDAQ:TAOX) is one of 450 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its peers? We will compare Synaptogenix to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability.

Valuation and Earnings

This table compares Synaptogenix and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Synaptogenix	$3,962.00	-$12.77 million	-0.34
Synaptogenix Competitors	$439.18 million	-$68.87 million	-9.40

Synaptogenix’s peers have higher revenue, but lower earnings than Synaptogenix. Synaptogenix is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Synaptogenix and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Synaptogenix Competitors	4780	9954	15974	366	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 72.63%. Given Synaptogenix’s peers stronger consensus rating and higher possible upside, analysts clearly believe Synaptogenix has less favorable growth aspects than its peers.

Risk & Volatility

Synaptogenix has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Synaptogenix’s peers have a beta of 10.34, meaning that their average share price is 934% more volatile than the S&P 500.

Profitability

This table compares Synaptogenix and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-277.76%	-150.79%
Synaptogenix Competitors	-2,625.49%	-359.63%	-43.39%

Summary

Synaptogenix peers beat Synaptogenix on 9 of the 13 factors compared.

Synaptogenix Company Profile

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.